Investec initiated coverage on shares of Alliance Pharma plc (LON:APH) in a research report report published on Wednesday morning. The firm issued a buy rating and a GBX 59 ($0.76) target price on the stock.

A number of other research firms have also recently weighed in on APH. FinnCap restated a buy rating and issued a GBX 58 ($0.75) price target on shares of Alliance Pharma plc in a report on Thursday, August 24th. Numis Securities Ltd restated a buy rating and issued a GBX 60 ($0.77) price target on shares of Alliance Pharma plc in a report on Wednesday.

Alliance Pharma plc (LON:APH) opened at 52.75 on Wednesday. The stock has a 50 day moving average of GBX 52.51 and a 200 day moving average of GBX 50.61. The company’s market cap is GBX 249.36 million. Alliance Pharma plc has a 52 week low of GBX 41.33 and a 52 week high of GBX 57.56.

ILLEGAL ACTIVITY WARNING: This piece of content was first published by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are accessing this piece of content on another website, it was illegally copied and reposted in violation of U.S. & international trademark and copyright legislation. The correct version of this piece of content can be accessed at https://www.thecerbatgem.com/2017/09/16/alliance-pharma-plc-aph-research-coverage-started-at-investec.html.

Alliance Pharma plc Company Profile

Alliance Pharma plc is a United Kingdom-based specialty pharmaceutical company. The Company is engaged in acquisition, marketing and distribution of pharmaceutical products. The Company operates in various business areas, such as Hydromol, secondary care, community and consumer products, established products and international.

Receive News & Stock Ratings for Alliance Pharma plc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alliance Pharma plc and related stocks with our FREE daily email newsletter.